tradingkey.logo
tradingkey.logo
Search

Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy

ReutersApr 6, 2026 12:19 PM

- Praxis Precision Medicines Inc PRAX.O:

  • PRAXIS PRECISION MEDICINES ANNOUNCES POSITIVE RESULTS FROM THE EMBRAVE PART A TRIAL OF ELSUNERSEN IN PATIENTS WITH SCN2A EARLY-ONSET DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY

  • PRAXIS PRECISION MEDICINES INC - ELSUNERSEN WELL-TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS UP TO 8 MG

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI